Form 4 for RARE Ultragenyx Pharmaceutical Inc.
Accepted 2024-06-12 00:00:00 ET · period of report 2024-06-12 · accession 0000950170-24-072621 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2024-06-12 | 2024-06-12 | RARE | Parschauer Karah Herdman | EVP, CLO | S - Sale | $45.00 | -9,806 | 58.0K | -14% | -$441.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-06-12 | S | D | 9,806 | $45.00 | 57,981 | D | — | — | (F1) Includes 447 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2024. (F2) Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |